Pharmaceutical

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Belcesiran?

Belcesiran is an antisense rnai oligonucleotide commercialized by Novo Nordisk, with a leading Phase II program in Alpha-1 Antitrypsin Deficiency (A1AD).

Mar 13, 2024 - 18:29
Belcesiran is an antisense rnai oligonucleotide commercialized by Novo Nordisk, with a leading Phase II program in Alpha-1 Antitrypsin Deficiency (A1AD).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

Next Article

Risk adjusted net present value: What is the current valuation of Johnson & John...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

Mabwell’s 9MW2821 gains FDA fast track status for breas...

Jul 16, 2024

STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access

STAT+: Pharmalittle: U.S. to impose inflation penalties...

Dec 15, 2023

STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024

STAT+: Pharmalittle: Weight-loss drugs fuel boom for fi...

Oct 10, 2023